SCHEMBL3282467

SCHEMBL3282467

O=C(O)c1cc(Cl)ccc1CO

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.59
TP53 P04637 1/20 0.59
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
TSHR P16473 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
CASP1 P29466 1/20 0.53
MAPT P10636 1/20 0.49
HSD17B10 Q99714 2/20 0.47
KDM4E B2RXH2 2/20 0.47
HPGD P15428 1/20 0.47
GAA P10253 1/20 0.46
MYC P01106 2/20 0.46
NR4A1 P22736 1/20 0.46
F7 P08709 1/20 0.44
F3 P13726 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ERCC5 P28715 1/20 0.43
FEN1 P39748 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27853748 0.86 ALDH1A1 (0.61) ALDH1A1TP53CA1CA2TSHR
SCHEMBL8482188 0.84 ALDH1A1 (0.59) ALDH1A1TP53CA1CA2TSHR
SCHEMBL22473881 0.84 ALDH1A1 (0.59) ALDH1A1TP53CA1CA2TSHR
SCHEMBL8482266 0.84 SMN1; SMN2 (0.59) ALDH1A1TP53CA1CA2TSHR
SCHEMBL3927953 0.82 ALDH1A1 (0.57) ALDH1A1TP53CA1CA2TSHR
SCHEMBL9204013 0.82 ALDH1A1 (0.57) ALDH1A1TP53CA1CA2TSHR
SCHEMBL1815043 0.82 ALDH1A1 (0.57) ALDH1A1TP53CA1CA2TSHR
SCHEMBL27675905 0.82 ALDH1A1 (0.57) ALDH1A1TP53CA1CA2TSHR
SCHEMBL6055057 0.82 ALDH1A1 (0.57) ALDH1A1TP53CA1CA2TSHR
SCHEMBL2334381 0.82 ALDH1A1 (0.57) ALDH1A1TP53CA1CA2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 US disclosed
US-20050107428-A1 Chemical compounds ASTRAZENECA AB (SE) 2005-05-19 US disclosed
EP-1478624-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2004-11-24 EP disclosed
WO-2003068743-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2003-08-21 WO disclosed
US-5856334-A ANTAGONIST FOR EOSINOPHILS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1999-01-05 US disclosed
EP-0773219-A1 IMIDAZOQUINOLINE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1997-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107428-A1 Chemical compounds CCR10, CCR3, CXCR5 ALDH1A1 3120/4885TP53 4765/4885CA1 3019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.